Cannabis Business Times Newsletter
| |
|
| | How antitrust regulators in Washington, D.C., are slowing down cannabis M&A deals—and changing the industry for the better. |
|
|
|
|
| | FSD Pharma, a Toronto-based biotech pharmaceutical R&D company, garnered a Nasdaq uplisting this winter and began trading on the U.S. market Jan. 9. |
|
|
|
|
| | The stock begins trading under the symbol ‘HUGE’ on Jan. 9, placing FSD Pharma in a select group of 12 Canadian-domiciled cannabis companies trading on the NYSE or NASDAQ. |
|
|
|
|
Like everything else in the cannabis industry, the future tends to come pretty fast. |
|
|
|
